SI-BONE stock ripped higher, closing at US$23.77, up 17.6% on the first full trading day after its Q3 2026 report. Traders focused on the headline beat in procedure activity and adjusted EBITDA, rather than on the fact the business is still posting a net loss of US$3.6 million for the quarter. For a medtech growth story, the real hook is the profit trend. Revenue reached US$55.7 million in Q3, and trailing twelve month losses have been steadily shrinking. In the short term, the chart grabbed...
SI-BONE Inc (SIBN) posted 14.5% revenue growth to $55.7 million, expanded adjusted EBITDA by 32% and reaffirmed full-year 2026 revenue guidance of $231 million to $233 million.
Motley Fool Press Release.
Detailed price information for Si-Bone Inc (SIBN-Q) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Detailed price information for Medtronic Inc (MDT-N) from The Globe and Mail including charting and trades.
SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address...
The mean of analysts' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
This is the newest page. Registered accounts read further back.